Olema Pharmaceuticals Inc
OLMA5.205USD
-0.125-2.35%
交易中 （美东）报价延迟15分钟
355.67M总市值
亏损市盈率 TTM
关于 Olema Pharmaceuticals Inc 公司
Olema Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司。该公司专注于发现、开发和商业化针对女性癌症的靶向疗法。其主要候选产品 OP-1250 是一种口服疗法，具有作为完全雌激素受体 (ER) 拮抗剂 (CERAN) 和选择性 ER 降解剂 (SERD) 的综合活性。该公司的 OP-1250 是一种口服小分子临床阶段候选产品，用于治疗内分泌驱动的癌症。OP-1250 作为单一疗法以及与细胞周期依赖性激酶 4 和 6 (CDK4/6) 抑制剂联合使用，在几种异种移植模型中表现出明显的肿瘤缩小效果，包括 ESR1 和 PIK3CA 突变和中枢神经系统 (CNS) 转移。目前该药物处于 I/II 期临床试验阶段，且处于 Ib/II 期临床试验阶段，与 palbociclib 联合用于治疗转移性 ER 阳性 (ER+)、人类表皮生长因子受体 2 阴性 (HER2-) 乳腺癌患者。
公司简介
公司代码OLMA
公司名称Olema Pharmaceuticals Inc
上市日期Nov 19, 2020
CEOMr. Sean P. Bohen, M.D., Ph.D.
员工数量96
证券类型Ordinary Share
年结日Nov 19
公司地址780 Brannan Street
城市SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94103
电话14156513316
网址https://olema.com/
公司代码OLMA
上市日期Nov 19, 2020
CEOMr. Sean P. Bohen, M.D., Ph.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. David C. Myles, Ph.D.
Mr. David C. Myles, Ph.D.
Chief Discovery and Non-Clinical Development Officer
Chief Discovery and Non-Clinical Development Officer
586.38K
+4.02%
Mr. Andrew Rappaport
Mr. Andrew Rappaport
Independent Director
Independent Director
385.96K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
83.88K
--
Ms. Shawnte M. Mitchell
Ms. Shawnte M. Mitchell
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Graham L. Walmsley, M.D., Ph.D.
Dr. Graham L. Walmsley, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Naseem Zojwalla, M.D.
Dr. Naseem Zojwalla, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ian Clark
Mr. Ian Clark
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Sean P. Bohen, M.D., Ph.D.
Mr. Sean P. Bohen, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Shane Kovacs
Mr. Shane Kovacs
Chief Operating and Financial Officer
Chief Operating and Financial Officer
--
--
Dr. Gorjan Hrustanovic, Ph.D.
Dr. Gorjan Hrustanovic, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. David C. Myles, Ph.D.
Mr. David C. Myles, Ph.D.
Chief Discovery and Non-Clinical Development Officer
Chief Discovery and Non-Clinical Development Officer
586.38K
+4.02%
Mr. Andrew Rappaport
Mr. Andrew Rappaport
Independent Director
Independent Director
385.96K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
83.88K
--
Ms. Shawnte M. Mitchell
Ms. Shawnte M. Mitchell
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Graham L. Walmsley, M.D., Ph.D.
Dr. Graham L. Walmsley, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Naseem Zojwalla, M.D.
Dr. Naseem Zojwalla, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
Bain Capital Life Sciences Investors, LLC
10.00%
Paradigm BioCapital Advisors LP
9.85%
BVF Partners L.P.
7.74%
Deep Track Capital LP
5.03%
BlackRock Institutional Trust Company, N.A.
4.85%
Other
62.52%
持股股东
持股股东
占比
Bain Capital Life Sciences Investors, LLC
10.00%
Paradigm BioCapital Advisors LP
9.85%
BVF Partners L.P.
7.74%
Deep Track Capital LP
5.03%
BlackRock Institutional Trust Company, N.A.
4.85%
Other
62.52%
股东类型
持股股东
占比
Hedge Fund
33.03%
Investment Advisor
28.42%
Investment Advisor/Hedge Fund
23.72%
Venture Capital
9.71%
Individual Investor
4.18%
Research Firm
3.71%
Bank and Trust
0.08%
Pension Fund
0.03%
Insurance Company
0.02%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
320
70.41M
102.91%
-12.31M
2025Q1
327
72.74M
106.44%
-11.08M
2024Q4
313
78.82M
113.63%
+3.60M
2024Q3
301
63.64M
110.87%
-10.05M
2024Q2
299
62.60M
111.72%
-7.29M
2024Q1
288
60.06M
107.83%
-1.82M
2023Q4
271
55.06M
100.31%
-2.15M
2023Q3
263
50.27M
92.75%
-945.85K
2023Q2
259
39.52M
96.98%
-9.43M
2023Q1
256
36.49M
89.86%
-12.60M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Bain Capital Life Sciences Investors, LLC
6.84M
10%
+2.44M
+55.54%
Mar 31, 2025
Paradigm BioCapital Advisors LP
6.74M
9.85%
-563.80K
-7.72%
Mar 31, 2025
BVF Partners L.P.
5.30M
7.74%
--
--
Mar 31, 2025
Deep Track Capital LP
3.44M
5.03%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.32M
4.85%
+40.22K
+1.23%
Mar 31, 2025
Logos Global Management LP
3.21M
4.69%
--
--
Apr 21, 2025
Franklin Advisers, Inc.
3.01M
4.4%
+2.74M
+1000.44%
Mar 31, 2025
MPM BioImpact LLC
2.93M
4.28%
+17.90K
+0.61%
Mar 31, 2025
The Vanguard Group, Inc.
2.87M
4.2%
+193.65K
+7.23%
Mar 31, 2025
Lightspeed Venture Partners
1.93M
2.82%
--
--
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.94%
ALPS Medical Breakthroughs ETF
0.2%
iShares Micro-Cap ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Biotechnology ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Global X Russell 2000 ETF
0.01%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.94%
ALPS Medical Breakthroughs ETF
占比0.2%
iShares Micro-Cap ETF
占比0.06%
ProShares Ultra Nasdaq Biotechnology
占比0.03%
Invesco Nasdaq Biotechnology ETF
占比0.03%
iShares Biotechnology ETF
占比0.02%
iShares Russell 2000 Value ETF
占比0.02%
Schwab U.S. Small-Cap ETF
占比0.01%
ProShares UltraPro Russell2000
占比0.01%
Global X Russell 2000 ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
